Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: Results on health-related quality of life and symptom burden. The MANTRA-PAF trial

Europace

Volumn 17, Issue 2, 2014, Pages 215-221

  Walfridsson, H ^a   Walfridsson, U ^a   Cosedis Nielsen, J ^b   Johannessen, A ^c   Raatikainen, P ^d   Janzon, M ^a   Levin, L A ^a   Aronsson, M ^a   Hindricks, G ^e   Kongstad, O ^f   Pehrson, S ^g   Englund, A ^h   Hartikainen, J ⁱ   Mortensen, L S ^j   Hansen, P S ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g University of Copenhagen   (Denmark)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

ⁱ KUOPIO UNIVERSITY HOSPITAL   (Finland)

^j UNI C   (Denmark)

more..

Author keywords

Antiarrhythmic drug treatment; Atrial fibrillation; Catheter ablation; First line therapy; Quality of life

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; PROPAFENONE;

ADULT; ANXIETY; ARRHYTHMIA SPECIFIC QUESTIONNAIRE IN TACHYCARDIA AND ARRHYTHMIA; ARTICLE; ASSESSMENT OF HUMANS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; EUROQOL FIVE DIMENSION QUESTIONNAIRE; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT WORRY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; THERAPY EFFECT; AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; COST OF ILLNESS; HEALTH STATUS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COST OF ILLNESS; FEMALE; FLECAINIDE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PROPAFENONE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84922433201     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu342     Document Type: Article

References (30)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
3. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.e1-19.
4. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-Term study. J Am Coll Cardiol 2003;42:185-97.
5. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118:2498-505.
6. Purerfellner H, Martinek M, Aichinger J, Nesser HJ, Kempen K, Janssen JP. Quality of life restored to normal in patients with atrial fibrillation after pulmonary vein ostial isolation. Am Heart J 2004;148:318-25.
7. Guedon-Moreau L, Capucci A, Denjoy I, Morgan CC, Perier A, Leplege A, et al. Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life. Europace 2010;12:634-42.
8. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303: 333-40.
9. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici Get al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006;27:216-21.
10. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006;48: 2340-7.
11. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
12. Jons C, Hansen PS, Johannessen A, Hindricks G, Raatikainen P, Kongstad O, et al. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. Europace 2009;11:917-23.
13. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587-95.
14. Valter L N-BH.Östgötens hälsa 2006. In. Linköping: Centre for Public Health Sciences. Linköping University Hospital; 2006.
15. Sullivan M, Karlsson J, Ware JE Jr. The Swedish SF-36 Health Survey-I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995;41:1349-58.
16. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996;94:1585-91.
17. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
18. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res 2010;19: 381-90.
19. Walfridsson U, Arestedt K, Stromberg A. Development and validation of a new arrhythmia-specific questionnaire in tachycardia and arrhythmia (ASTA) with focus on symptom burden. Health Qual Life Outcomes 2012;10:44.
20. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J AmColl Cardiol 2000;36:1303-9.
21. Reynolds MR, Walczak J, White SA, Cohen DJ, Wilber DJ. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes 2010;3:615-23.
22. Weerasooriya R, Jais P, Hocini M, Scavee C, MacLe L, Hsu LF, et al. Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation. Heart Rhythm 2005;2:619-23.
23. Tanner H, Makowski K, Roten L, Seiler J, Schwick N, Muller Cet al. Catheter ablation of atrial fibrillation as first-line therapy-A single-centre experience. Europace 2011; 13:646-53.
24. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40.
25. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, et al. HRS/EHRA/ ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up.Areport of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart RhythmSociety. Europace 2007;9:335-79.
26. Walfridsson U, Walfridsson H, Arestedt K, Stromberg A. Impact of radiofrequency ablation on health-related quality of life in patients with paroxysmal supraventricular tachycardia compared with a norm population one year after treatment. Heart Lung 2011;40:405-11.
27. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-Analyses. Circ Arrhythm Electrophysiol 2009;2:349-61.
28. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005;112:307-13.
29. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-9.
30. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, MungerTM et al. Long-Term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 2010;55:2308-16.